Jan. 12 at 3:35 PM
$ADPT Adaptive Biotechnologies Shares Rise on Preliminary Earnings
Jan 12, 2026, 07:27 GMT-6Less than 1 min read
ADPT
+12.94%
Shares of Adaptive Biotechnologies climbed after the company reported preliminary fourth-quarter and full-year results.
The stock rose 14% to
$18 in premarket trading Monday. Through Friday's close, shares have more than doubled over the past year.
The biotechnology company said before the bell that it expects to report fourth-quarter revenue of
$72 million, up 51% from a year earlier. Analysts polled by FactSet were expecting revenue of
$59.3 million.
For the year, revenue is projected to come in at
$277 million, marking a 55% increase from 2024. Wall Street had modeled full-year revenue of
$264.7 million.
Chief Executive Chad Robins called 2025 a pivotal year for the company. Looking ahead, the company expects sales of ClonoSEQ--which helps doctors detect, quantify and monitor small amounts of cancer known as measurable residual disease,
